Overview
Lobbying Costs
500,000€ - 599,999€
Financial year: Feb 2021 - Jan 2022
Lobbyists (Full time equivalent)
0.25 Fte (1)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
PHOENIX Pharma SE (PHOENIX group)
EU Transparency Register
108461232380-63 First registered on 21 Aug 2018
Goals / Remit
The PHOENIX group, headquartered in Mannheim, is a leading healthcare provider in Europe. Active in 26 countries, the company offers unique geographical coverage throughout Europe, making a vital contribution to comprehensive healthcare with more than 39,000 employees. The PHOENIX group’s vision is to be the best integrated healthcare provider – wherever it is active.
The PHOENIX group considers itself to be a link between manufacturer and patient. Pharmaceutical manufacturers, pharmacies, doctors, hospitals, health insurance funds, and patients across Europe can benefit from its service offering. In pharmaceutical wholesale, the PHOENIX group is active with 161 distribution centres in 26 countries and supplies pharmacies and medical institutions with medicines and other health products. Numerous other products and services for pharmacy customers complete the portfolio – from assistance in advising patients to modern goods management systems to pharmacy cooperation programmes.Main EU files targeted
PHOENIX group has been actively involved in the Falsified Medicines Directive (FMD) and its Delegated Regulation (EU) 2016/161. Via the European body representing pharmaceutical full line wholesalers, GIRP, PHOENIX has supported both the European associations and the European institutions in understanding better the impact such legislation has on the pharmaceutical wholesale sector. PHOENIX has provided factual examples that helped shape the drafting of the Delegated Regulation. Following the publishing of the legislation, PHOENIX is constantly involved in the implementation process together with the other supply chain partners and their representative bodies at European level (EFPIA, PGEU, Medicines for Europe and EAEPC) , contributing to the clarifications of various topics with regard to FMD implementation.
Besides FMD, PHOENIX has been supported the drafting by the Commission of the Good Distribution Practice (GDP) guidelines. Other initiatives where PHOENIX group was involved refer to Commission working groups on e-health and active and healthy ageing and participation in numerous European Parliament debates concerning the healthcare sector.Address
Head Office
Pfingstweidstrasse 10 -12
Mannheim 68199
GERMANYEU Office
Pfingstweidstrasse 10 -12
Mannheim 68199
GERMANYWebsite
-
People
Total lobbyists declared
1
Employment time Lobbyists 25% 1 Lobbyists (Full time equivalent)
0.25
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 13 May 2022
Name Start date End Date Gavrilo NIKOLIC 07 Dec 2023 06 Dec 2024 Ronan BRETT 27 Jun 2023 26 Jun 2024 Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
www.girp.eu
www.phagro.de
www.m-r-n.com
www.world50.comMember organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Feb 2021 - Jan 2022
Lobbying costs for closed financial year
500,000€ - 599,999€
Major contributions in closed year
None declared
Intermediaries for closed year
None declaredIntermediaries for current year
None declaredClosed year Costs
500,000€ - 599,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
None
Other activities
None declared
- Meetings
Meetings
None declared
- Meetings